Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.2% |
| 2 | Technology | 14.19% |
| 3 | Financials | 12.33% |
| 4 | Consumer Staples | 10.22% |
| 5 | Industrials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1526
Home BancShares
HOMB
$6.3B
| $6.57M | 0.01% |
+263,984
| New | +$6.58M |
|
1527
La-Z-Boy
LZB
$1.68B
| $6.55M | 0.01% |
+201,676
| New | +$5.66M |
|
1528
Saga Communications
SGA
$62.6M
| $6.55M | 0.01% |
143,258
+5,058
| +4% | +$251K |
|
|
GSS
1529
DELISTED
Golden Star Resources Ltd.
GSS
| $6.55M | 0.01% |
2,013,898
-82,860
| -4% | -$295K |
|
|
EMCI
1530
DELISTED
EMC INS Group Inc
EMCI
| $6.54M | 0.01% |
235,350
+7,978
| +4% | +$219K |
|
|
TVTY
1531
DELISTED
Tivity Health, Inc. Common Stock
TVTY
| $6.52M | 0.01% |
163,589
-273,300
| -63% | -$9.14M |
|
|
CDR
1532
DELISTED
Cedar Realty Trust, Inc
CDR
| $6.51M | 0.01% |
203,470
-38,591
| -16% | -$1.31M |
|
|
ESSA
1533
DELISTED
ESSA Bancorp
ESSA
| $6.49M | 0.01% |
440,700
+5,800
| +1% | +$86.1K |
|
|
OME
1534
DELISTED
Omega Protein
OME
| $6.49M | 0.01% |
362,300
+39,874
| +12% | +$745K |
|
1535
Griffon
GFF
$4.71B
| $6.48M | 0.01% |
295,300
-300
| -0.1% | -$6.9K |
|
1536
Century Casinos
CNTY
$36M
| $6.47M | 0.01% |
878,500
+220,300
| +33% | +$1.73M |
|
1537
Armstrong World Industries
AWI
$7.68B
| $6.46M | 0.01% |
140,464
-160,336
| -53% | -$7.19M |
|
|
EPAY
1538
DELISTED
Bottomline Technologies Inc
EPAY
| $6.46M | 0.01% |
251,300
+8,158
| +3% | +$200K |
|
1539
Mistras Group
MG
$576M
| $6.45M | 0.01% |
293,700
-16,800
| -5% | -$362K |
|
|
CALL
1540
DELISTED
magicJack VocalTec Ltd
CALL
| $6.44M | 0.01% |
894,768
-7,868
| -0.9% | -$60K |
|
|
MDRX
1541
DELISTED
Veradigm Inc. Common Stock
MDRX
| $6.44M | 0.01% |
+504,567
| New | +$6.13M |
|
1542
Kennametal
KMT
$2.39B
| $6.43M | 0.01% |
+171,900
| New | +$6.73M |
|
1543
Moelis & Co
MC
$5.08B
| $6.42M | 0.01% |
165,144
-278,716
| -63% | -$10.4M |
|
|
AMRI
1544
DELISTED
Albany Molecular Research Inc
AMRI
| $6.41M | 0.01% |
295,542
+147,200
| +99% | +$2.67M |
|
|
GMS
1545
DELISTED
GMS Inc
GMS
| $6.4M | 0.01% |
227,700
+9,200
| +4% | +$309K |
|
1546
Coca-Cola Consolidated
COKE
$12.5B
| $6.37M | 0.01% |
278,270
-94,730
| -25% | -$2.05M |
|
1547
CytomX Therapeutics
CTMX
$736M
| $6.37M | 0.01% |
410,900
+176,100
| +75% | +$2.65M |
|
|
PAMT
1548
PAMT Corp
PAMT
$270M
| $6.36M | 0.01% |
1,342,800
-86,800
| -6% | -$376K |
|
|
ELOS
1549
DELISTED
Syneron Medical Ltd
ELOS
| $6.36M | 0.01% |
580,780
-523,800
| -47% | -$5.74M |
|
1550
Associated Banc-Corp
ASB
$6.1B
| $6.36M | 0.01% |
252,316
-210,863
| -46% | -$5.18M |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.